海南黎族高血压人群血管紧张素Ⅰ转化酶基因多态性与血脂的关系

目的:观察血管紧张素Ⅰ转化酶(ACE)基因16内含子插入/缺失(I/D)多态性与海南黎族高血压人群血脂的关系。方法:根据血压的的正常与否,将研究对象分为对照组与高血压组;采血检测血脂水平,检测血中ACE基因16内含子I/D多态标记,分析各基因型与血脂关系。结果:2组之间DD、DI、II基因型频率及D、I等位基因频率均差异无统计学意义。高血压组各基因型之间血脂水平差异亦无统计学意义。结论:ACE基因I/D多态性与黎族高血压无显著关联;与黎族高血压患者血脂水平无明显相关。     

血管紧张素转化酶基因多态性与原发性高血压的关系

目的研究血管紧张素转化酶（ＡＣＥ）基因的插入／缺失（Ｉ／Ｄ）多态性与原发性高血压的关系。方法应用ＰＣＲ的方法分别检测７２例原发性高血压患者和９３例正常血压组的ＡＣＥ基因第１６内含子的Ｉ／Ｄ多态性。结果共得到３种基因型：纯合缺失型（ＤＤ），纯合插入型（Ｉ），杂合型（ＩＤ）。原发性高血压患者Ｄ等位基因的频率（０．６２）高于健康对照组（０．４８）（Ｐ＜０．０５）。结论ＡＣＥ基因的Ｉ／Ｄ多态性可能与原发性高血压有关。     

血管紧张素转化酶基因多态性对血清血管紧张素转化酶水平及血脂的影响

为探讨血管紧张素转化酶基因多态性对本地人群高血压患者和正常人血清血管紧张素转化酶及血脂水平的影响,采用聚合酶链反应技术,对118例高血压患者和98例正常人的血管紧张素转化酶基因插入/缺失多态性进行分型,并检测血清血管祭张素转化酶活性及血脂含量。结果发现,高血压组血管紧张素转化酶三种基因型(缺失纯合子型、插入纯合子型和杂合子型)及插入/缺失等位基因的频率与正常对照组比较差异无统计学意义(X2=0.468,P=0.791;X2=0.379,P=0.538)。血清血管紧张素转化酶活性在三种基因型之间差异有显著性意义(F=17.107,P=0.000)。高血压组总胆固醇、低密度脂蛋白胆固醇、脂蛋白(a)高于正常对照组(P<0.05);高血压组三种基因型之间血脂各指标含量及正常对照组三种基因型之间总胆固醇、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇和载脂蛋白B含量差异有显著性意义(P<0.05)。此结果提示,血管紧张素转化酶基因多态性与血清血管肾张素转化酶活性及血脂含量有关,缺失纯合子型高血压患者血清血管紧张素转化酶活性最高且易患高脂血症。     

血管紧张素转化酶基因多态性与老年人高血压合并左心室肥厚的探讨

目的 探讨血管紧张素转化酶（ACE）基因插入／缺失（I／D）多态性与老年人高血压合并左心室肥厚（LVH）的关系。同时测定血清ACE水平,观察与ACE基因多态性的关系。方法 应用聚合酶链反应（PCR）技术102例老年人进行ACE基因I／D多态性检测,其中正常对照者41例,高血压无心脑血管合并症（CCVD）患者35例,高血压合并LVH者26例。同时,用紫外分光光度法测定其中32例正常人和29例高血压病患者的血清ACE浓度。结果 高血压合并LVH组DD基因型频率0．385和D等位基因频率0．596分别显著高于正常对照组的0．122和0．378（均为P＜0．05）,以及高血压无CCVD组的0．114和0．386（均为P＜0．05）。同时发现DD型者血清ACE水平显著高于Ⅱ型（P＜0．05）。结论 ACE基因缺失多态性可能是老年高血压合并LVH易患者的重要遗传标志。     

原发性高血压血管紧张素原、血管紧张素转化酶、心房钠尿肽基因多态性分析

目的 研究中国南方汉族人群中血管紧张素原、血管紧张素转化酶及心房钠尿肽基因多态性与原发性高血压的关系.方法 选择原发性高血压患者81例及对照者120例,采用基因芯片技术检测血管紧张素原、血管紧张素转化酶及心房钠尿肽基因多态性,并比较其基因型及等位基因频率.结果 高血压组血管紧张素原TT基因型频率为53.1%,与对照组(45.8%)比较,差异无统计学意义(P>0.05);高血压组患者血管紧张素转化酶DD基因型频率为48.1%,与对照组(4.2%)比较,差异具有统计学意义(P<0.001);高血压组心房钠尿肽CC基因型频率为6.1%,与对照组(8.3%)相比,差异亦无统计学意义(P>0.05).结论 血管紧张素转化酶基因多态性可能与原发性高血压的发生有相关性.     

脑梗死患者血管紧张素转化酶基因多态性与血浆血管紧张素Ⅱ水平研究

探讨脑梗死患者血管紧张素转化酶基因多态性与血浆血管紧张素Ⅱ水平的关系。应用聚合酶链反应测定 173例高血压脑梗死患者血管紧张素转化酶基因插入 /缺失 (D/I)多态性以及用酶联免疫吸附测定法测定血浆血管紧张素Ⅱ水平 ,并与正常对照组比较。结果发现 ,脑梗死组血管紧张素转化酶DD基因型频率为 0 .39,明显高于对照组的 0 .2 4 (P <0 .0 1)。进一步分析发现这种异常与发病年龄≤ 6 0岁组血管紧张素转化酶DD基因型频率明显增高有关。脑梗死组中血浆血管紧张素Ⅱ水平为 2 9.8± 10 .2ng/L ,与对照相比差异无显著性意义 (P >0 .0 5 ) ,但血管紧张素转化酶DD基因型者血浆血管紧张素Ⅱ水平显著高于对照组和同组DI基因型和Ⅱ基因型者 (P <0 .0 1)。发病年龄≤ 6 0岁血管紧张素转化酶DD基因型者血浆血管紧张素Ⅱ水平增高最明显。结果提示 ,血管紧张素转化酶DD基因型是脑梗死发病危险因素 ,发病年龄小于 6 0岁的脑梗死者可能与血管紧张素转化酶D等位基因频率增高、血浆血管紧张素Ⅱ水平增高有关。     

血管紧张素转化酶2基因多态性与原发性高血压的关系

目的研究血管紧张素转化酶2基因（ACE2-G8790A）单核苷酸多态性（SNP）与原发性高血压的关系。方法用PCR—RFLP及电泳分析法进行基因分型,SPSS软件分析各等位基因与原发性高血压的相关性。结果高血压患者与对照组的基因型、等位基因频率比较均有显著性差异（P=0．020,0．001）。高血压组GG、GA和AA基因型在女性中的分布频率分别为29．2％、42．4％和28．4％,女性对照组相应基因型的频率分别为29．3％、56．6％和14．1％,两组比较有显著性差异;G,A等位基因频率在高血压组分别为53．0％和47．0％,对照组相应的等位基因频率为63．3％,36．7％,两组比较差异有显著性（P〈0．01）。结论ACE2-G8790A基因多态性与原发性高血压相关。     

血管紧张素转化酶基因多态性与高血压病人胰岛素抵抗相关性的研究

目的　探讨血管紧张素转化酶 (ACE)基因多态性 ,血管紧张素原 (AGT)基因突变与高血压及胰岛素抵抗的关系。方法　用聚合酶链反应 (PCR)检测 76例原发性高血压及 2 8例正常血压者的ACE基因插入 /缺失 (I/D)多态性及AGT基因位点突变 ,同时进行口服葡萄糖耐量及胰岛素释放试验 ,以空腹血糖及空腹胰岛素乘积倒数的对数值(ISI) ,胰岛素曲线下面积IS AUC作为胰岛素敏感性指标。结果　 (1)ACE基因多态性在高血压和正常血压组无显著性差异 ,而AGTT2 35等位基因频率在高血压组高于正常对照组 (0 4 3vs0 32 ,P <0 0 5 )。 (2 )无论是高血压还是正常血压者ACE基因DD型者的ISI均明显低于ID和II型 ,IS AUC显著高于ID和II型〔ISI:- 4 31± 0 2 0vs -3 6 3± 0 2 2和 - 3 2 7± 0 2 4 ,P <0 0 1;IS(AUC) :2 11 1± 5 6 8vs 135 7± 5 4 7、12 6 8± 5 1 7mu·L-1,P <0 0 1〕 ,而AGT基因T2 35 ,T174基因突变与胰岛素抵抗无关 (P >0 0 5 )。结论　ACE基因DD型而非AGT基因可能参与高血压病人及正常血压者胰岛素抵抗的基因调节 ,这可能是ACE基因DD型易发生心血管危险的机制之一     

原发性高血压患者血管紧张素转化酶基因多态性与血管内皮损伤的相关性

目的:探讨原发性高血压(EH)患者血管紧张素转化酶(ACE)基因I/D多态性与血管内皮损伤的相关性。方法:选择初次诊断的EH患者68例,采用聚合酶链反应(PCR)方法进行ACE基因分型,并测定其血浆可溶性P选择素(sP-selectin)、血栓烷B2(TxB2)和6-酮-前列腺素F1α(6-keto-PGF1α)浓度和血管假性血友病因子(v WF)抗原水平。结果:根据等位基因分布,EH患者分为DD型(18例)、ID型(26例)和II型(24例)3组;DD型的血浆sP-selectin、TxB2浓度和v WF抗原水平明显高于其他2型(P<0·05),而6-keto-PGF1α浓度则是DD型最低(P<0·05)。多因素Logistic回归分析显示ACE/DD基因型是引起患者血浆sP-selectin、TxB2、v WF升高和6-keto-PGF1α降低的独立危险因子。结论:ACE/DD基因型的EH患者较ACE/ID型和ACE/II型具有更为明显的血管内皮损伤倾向。     

原发性高血压患者血管紧张素转化酶和血管紧张素受体基因多态性的研究

目的　探讨血管紧张素转化酶 ( ACE)及血管紧张素 - 1型受体 ( AT1 R)基因多态性与原发性高血压 ( EHT)的关系。方法　应用聚合酶链反应及 PCR加酶解方法检测 1 50例健康人 ( NT)及 1 52例 EHT患者 ACE I/ D基因多态性的 ACE及 AT1 R A1 1 6 6 C突变。结果　 EHT组ACE I/ D基因多态性等位基因频率 I为 0 .50 ,D为 0 .50 ,D等位基因频率及基因型频率显著高于 NT组 ( P<0 .0 5) ;而两者之间的 AT1 R A1 1 6 6 C的C等位基因频率差异无显著性 ( P>0 .0 5)。结论　 ACE基因可能是 EHT的重要遗传因素 ,AT1 R基因 A1 1 6 6 C多态性与 EHT无关     

海南黎族冠心病与血管紧张素转化酶基因多态性的关系

目的:研究海南黎族人群血管紧张素转化酶(ACE)基因多态性与冠心病(CHD)关系.方法:采用聚合酶链反应(PCR)技术,对海南黎族150例CHD患者(CHD组)和150例正常人(正常对照组)的ACE基因插入/缺失(I/D)多态性进行检测,观察DD、DI,II基因型频率及等位基因频率,并对所有普通PCR定为DD型的样本进行插入特异性PCR检测,以减少误分型率.结果:CHD组DD、DI、II基因的频率分别是24.7%、32.7%、42.6%;D及I等位基因频率分别为41.0%、59.6%;正常对照组DD、DI、II基因型频率分别为14.0%、44.0%、42.0%,D及I等位基因频率分别为36.0%、64.0%;2组之间的DD、DI、II基因频率及D、I等位基因频率,均差异有统计学意义(P＜0.05).结论:ACE I/D多态性与黎族CHD有显著关联,是海南黎族CHD的主要致病基因.早期应用ACE抑制剂、血管紧张素受体拮抗剂防治,有十分重要意义.     

A study of lipoprotein lipase gene intron 8 polymorphisms in Chinese Han race essential hypertension patients

OBJECTIVE: To investigate the association of lipoprotein lipase gene intron 8 polymorphisms and Essential Hypertension in Han race Chinese. METHODS AND RESULTS: 116 patients with Essential Hypertension were enrolled and another 116 normal people were served as controls. All cases were examined for the genotypes of intron 8 in lipoprotein lipase gene by the methods of polymerase chain reaction restriction fragment length polymorphism, and the serum lipoprotein levels were also observed. Results showed that body mass index blood pressure and the serum triglyceride level were obviously increased in the Essential Hypertension group. The genotype and allele frequency of intron 8 in lipoprotein lipase in the Essential Hypertension group showed obvious differences compared with the control group. Serum triglyceride levels were higher in the patients with H+H+ genotype than in those in non H+H+ genotype of intron 8 in lipoprotein lipase by HindIII digestion. The systolic blood pressure showed a decreasing tendency among the H+H+ genotype, the H+H- genotype and the H-H- genotype individuals. CONCLUSION: The results suggest that lipoprotein lipase may be an important genetic factor associated with the Chinese Han race Essential Hypertension patients. The polymorphisms of intron 8 in lipoprotein lipase influence the blood-lipid metabolism, induce blood vessel rebuilding and play an important role in the invasion and development of Essential Hypertension.     

A double-blind comparative study of doxazosin and nitrendipine in patients with mild-to-moderate essential hypertension

The antihypertensive efficacy and safety of doxazosin, a selective α₁-inhibitor, were compared with nitrendipine. Seventy-two hypertensive patients were entered into the 18-week, double-blind parallel group study, which involved three phases: a 4-week baseline period, a 10-week period in which patients received 1 to 8 mg of doxazosin or 10 and 20 mg of nitrendipine once daily, and a 4-week maintenance period. For all patients, the mean final daily doses were 2.5 mg for doxazosin and 13.9 mg for nitrendipine. In efficacy evaluable patients the percentages of therapy successes (standing diastolic blood pressure ≤90 mm Hg with ≥5 mm Hg reduction or ≥10 mm Hg decrease) were comparable for doxazosin (94%) and nitrendipine (91%), as was the proportion in whom blood pressure was “normalized” (standing diastolic blood pressure ≤90 mm Hg). 91% and 85, respectively. Blood pressures (diastolic and systolic in supine and standing positions) were significantly reduced (p < 0.05) at all visits in both treatment groups. Ten patients (28%) in each treatment group experienced at least one adverse event. No clinically significant laboratory changes were apparent in either the doxazosin or nitrendipine groups, and no trends were observed with regard to organ systems or correlations with dose or duration of treatments. The investigators' global assessment of efficacy was rated excellent or good for all doxazosin-treated patients and excellent or good for 32 and fair for four in the nitrendipine group. The investigators' global assessment of patient toleration of doxazosin was excellent or good for 34 patients and poor for two. Toleration of nitrendipine was excellent or good in 33 patients and fair in three. Lipid parameters did not differ significantly between groups. From baselline to final visit there were highly significant reductions (p < 0.001) in the calculated coronary heart disease risk scores on the basis of the Framingham equation, for both treatment groups.     

eNOS基因多态性与湖北汉族人群原发性高血压相关

采用聚合酶链反应结合聚丙烯酰胺凝胶电泳检测湖北汉族316例原发性高血压患者和338名正常人内皮型一氧化氮合酶(eNOS)基因第4内含子多态性,发现eNOS基因该位点多态性(ab+aa等位基因)与原发性高血压显著相关(P＜0.05),可能是湖北汉族人群原发性高血压的一个易感标记.     

A comparative study of doxazosin versus atenolol in mild-to-moderate hypertension

Doxazosin, a quinazoline derivative, is a selective α₁-inhibitor that reduces calculated coronary heart disease risk by lowering blood pressure while favorably affecting blood lipid levels. The aim of this study was to compare the efficacy and toleration of doxazosin with atenolol, one of the most frequently used cardioselective β-blockers in Italy. Forty patients with mild-to-moderate hypertension were treated with either atenolol (100 mg) or doxazosin (mean dose, 3.3 mg) once daily for 8 weeks. Both drugs significantly reduced supine and standing systolic and diastolic blood pressures. Atenolol induced marked bradycardia, whereas doxazosin had very little effect on heart rate. Doxazosin produced a favorable effect on blood lipid levels by decreasing triglyceride and total cholesterol levels and increasing high-density lipoprotein cholesterol and high-density lipoprotein total cholesterol ratio. Atenolol had exactly the opposite effect on blood lipid levels. Both drugs had equivalent toleration profiles. It was concluded that doxazosin was as effective as atenolol in reducing elevated supine and standing blood pressures. In addition, doxazosin had a beneficial effect on lipid profiles and minimal effect on heart rate. Therefore doxazosin may reduce calculated coronary heart disease risk in hypertensive patients.     

HMGB1 gene polymorphism is associated with hypertension in Han Chinese population

Abstract

Background: High-mobility group box 1 protein (HMGB1) acts as a proinflammatory cytokine by activating pattern recognition receptors (PRRs), including Toll-like receptor 4 (TLR4) and the receptor of AGE (AGER) with oxidative injury. Animal study proved that HMGB1 contributed to the pathogenesis of experimental pulmonary hypertension (HT) via activation of TLR4. The aim of this study is to test whether HMGB1 harbor genetic susceptibility to HT in a Chinese population. Methods: A case–control study comprising 2012 HT cases and 2210 controls was used to evaluate the association of three tagging single nucleotide polymorphism (tagSNPs) in HMGB1 gene with HT and blood pressure. Logistic regression model was used to adjust confounding factor for HT and general linear model (GLM) was applied to compare blood pressure levels between genotypes in cases and controls. Results: Single locus analysis showed that there was no statistical association of three tagSNPs with HT after adjustment for the covariates. Further stratification analysis found that rs2249825 was significantly associated with HT in ≥55 years groups, ORs (95% CI) of additive model and dominant model were 1.208 (1.029–1.417) and 1.212 (1.020–1.441), and p values were 0.021 and 0.029, respectively. Quantitative trait analysis indicated that DBP had a linear decrease with the variations of rs2249825 in both untreated HT group (p?=?0.002) and control group (p?=?0.034) respectively. Conclusions: Our finding suggests that rs2249825 of HMGB1 genetic polymorphisms are significantly associated with HT and diastolic blood pressure, and the genetic effect on HT is modulated by age.     

Hemodynamic effects of urapidil in patients with pulmonary hypertension. A comparative study with hydralazine

Vasodilator therapy for pulmonary hypertension ideally should cause a proportionately greater reduction of resistance in the pulmonary vascular bed than in the systemic circulation. This should limit the occurrence of systemic hypotension, which can complicate the use of most vasodilator drugs. Urapidil is a new vasodilator that acts by postsynaptic alpha 1-blockade while inhibiting the aortic pressure baroreceptor reflex and reducing central sympathetic tone. We investigated and compared the short-term effects of Urapidil and hydralazine in 10 patients suffering varying degrees of pulmonary hypertension. Each patient received either 0.35 mg/kg hydralazine or 0.75 mg/kg Urapidil intravenously on 2 sequential days in a randomized order. The main effect of Urapidil was to decrease the mean pulmonary artery pressure in all 10 patients from 44 +/- 4 to 37 +/- 3.5 mm Hg (p less than 0.001). After Urapidil infusion, the mean decrease of resistance in the pulmonary vascular bed (32%) exceeded that in the systemic circulation (25%). In contrast, pulmonary artery pressure remained unchanged with hydralazine, and predominant systemic vasodilation occurred: systemic vascular resistance decreased by 45%, whereas pulmonary vascular resistance decreased by 25%. Hydralazine markedly increased the cardiac index and induced tachycardia. Urapidil maintained the heart rate nearly constant and only slightly increased the cardiac index, thereby fostering the diastolic emptying of the pulmonary circulation. No significant change in arterial oxygenation occurred with either drug, although arterial oxygen partial pressure tended to increase with hydralazine. Urapidil may be a promising drug in the treatment of patients with pulmonary hypertension.     

Association between CYP3A5 genotypes with hypertension in Chinese Han population: A case-control study

Background: The association of CYP3A5 gene polymorphisms with hypertension in the Chinese population is unknown. We explored the association between the CYP3A5 (rs776746) gene and hypertension in the Chinese Han population. Methods: Using a case-control design, 340 cases and 254 controls were enrolled from the Third Affiliated Hospital of South Medical University between July and December of 2015. We used a standardized questionnaire to collect data regarding age, sex, smoking, drinking, family history of hypertension, and physical exercise. Height and weight were measured, and the body mass index (BMI) was calculated by weight/height². Blood pressure was measured three times after 5 min of rest with at least 15 s between measurements, and the mean was considered the final BP. A Clinical examination was conducted. Results: A total of 594 participants, including 340 cases and 254 controls, were entered into the analyses. The genotype frequencies of the CYP3A5 G>A polymorphism did not deviate from the Hardy-Weinberg equilibrium. The genotype frequencies among the cases were 38.8% (GA, 132 individuals), 42.9% (GG, 146 individuals), and 18.2% (AA, 62 individuals). The differences in genotype between the cases and the controls were statistically significant. The AA genotype was associated with an elevated risk of hypertension after adjusting for potential confounders in Model 2. There was no interaction between smoking and the CYP3A5 genotype, while the interaction between drinking and the CYP3A5 genotype was significant. Conclusion: The CYP3A5 gene may be associated with the risk of hypertension in the Chinese Han population, and this effect may be exacerbated by drinking.     

A parallel group randomised comparative study of felodipine and nifedipine in hypertension.

We compared the antihypertensive effects and tolerability of a new calcium channel antagonist felodipine with nifedipine in an open randomised parallel group study in 49 patients with moderate hypertension (diastolic blood pressure 105-120 mm Hg). After two weeks run in period felodipine 5 mg and 10 mg once daily was compared with nifedipine 10 mg tid for an active treatment period of 4 weeks. Twenty three patients (mean age 42 +/- 10 years) received felodipine 5 mg once daily for first 2 weeks and 10 mg once daily for subsequent 2 weeks. Twenty six patients (mean age 45 +/- 9 years) received nifedipine 10 mg tid for 4 weeks. The mean reduction in supine diastolic blood pressure in two groups was 17 +/- 6 mm Hg (nifedipine) and 19 +/- 8 mm Hg (felodipine) (p = NS). The goal diastolic blood pressure of less than or equal to 90 mm Hg was achieved in 31 percent (nifedipine group) and 43.5 percent (felodipine group) of patients (p = NS). Side effects were common with both drugs; however, the tolerability was better with felodipine than with nifedipine. In conclusion felodipine was as effective as nifedipine and had the advantage of once a day dosage.     

肝炎肝硬变门脉高压症患者脾切除与脾切除后自体脾组织移植的临床对照研究

目的 探讨脾切除／自体脾组织移植在肝硬变门脉高压症治疗中的作用。方法 42例肝炎肝硬变门脉高压症患者行脾切除和贲门周围血管离断术治疗。其中20例同时行自体脾组织移植。观察脾切除组与脾切除自体脾组织移植组手术前后白细胞、血小板、血清免疫球蛋白、补体的含量、NK细胞活性以及T淋巴细胞转化率的变化。结果 两组IgG和IgA术前与术后相比较无显著差异（P〉0．05）。移植组术后2周、6月和1年血清IgM水平与脾切除组差异有统计学意义（P〈0．05）；术后3月两组IgM有显著性差异（P〈0．01）。移植组C3术后明显升高，脾切除组C3值术后较术前无明显变化。移植组与脾切除组C3术后3个月至1年有显著性差异（P〈0．01）。脾切除组术后半年NK细胞活性明显低于术前水平，移植组与脾切除组NK细胞术后3个月、6个月、1年与术前有显著性差异（P〈0．01）。移植组与脾切除组T淋巴细胞转化率术后3个月至1年有显著性差异（P〈0．01）。结论 肝炎肝硬变门脉高压症患者在脾切除／自体脾组织移植术后的免疫功能较非移植组有明显的提高。